

SENSIMED RECEIVES BROAD SCIENTIFIC AND BUSINESS RECOGNITION

Lausanne, June 16th, 2008 – Sensimed AG announced today that the company has been recently recognized for its outstanding achievements on scientific, management and business potential perspectives.

Sensimed was awarded by Pfizer France for the best communication in the field of glaucoma during the Congress of the French Association of Ophthalmology which took place in May in Paris. This award, given by a panel of eight ophthalmologists and sponsored by one of the leading players in the field of glaucoma, recognizes Sensimed as a leading solution provider in its field.

The Commission for Technology and Innovation (CTI) of Switzerland, which supports innovative and promising enterprises in the high-tech sector, also awarded Sensimed with the CTI Label. This label is the end result of several months evaluation conducted by industrial experts in several fields including business and financial strategy and modeling, market access, organizational structure and management, intellectual property and technology review.

At a pan-European level, Sensimed was named a Finalist of Red Herring 100 Europe, an award given to the top 100 private technology companies based in the EMEA (Europe, Middle East and Africa) region each year. Red Herring's editorial staff rigorously evaluated several hundred private companies through a careful analysis of financial data and subjective criteria, including quality of management, execution of strategy, and dedication to research and development. Only one other life science company was named along with Sensimed by Red Herring this year.

About Sensimed: Sensimed AG has developed a new, patented, non-invasive diagnostic test system that will significantly improve identification and treatment of glaucoma by monitoring intra-ocular pressure around the clock – both in glaucoma patients as well as in individuals at high risk for the disease. With its diagnostic test system, Sensimed is addressing a growing medical need: In the United States alone there are 10 million glaucoma related doctors' visits each year; and a further 30 million people are, based on their age and other factors, considered to be at high risk for glaucoma. Sensimed completed in January 2008 a CHF 8m Series A round of financing with Wellington Partners, Vinci Capital - Renaissance PME and Blue Ocean Ventures.

Contact information: Jean-Marc Wismer, CEO, www.sensimed.ch